Włoczkowska Olga, Perła-Kaján Joanna, Smith A David, de Jager Celeste, Refsum Helga, Jakubowski Hieronim
Department of Biochemistry and Biotechnology Poznań University of Life Sciences Poznań Poland.
OPTIMA Department of Pharmacology University of Oxford Oxford UK.
Alzheimers Dement (N Y). 2021 Mar 31;7(1):e12159. doi: 10.1002/trc2.12159. eCollection 2021.
Elevated homocysteine (Hcy) and related metabolites accelerate Alzheimer's disease. Hcy-lowering B vitamins slow brain atrophy/cognitive decline in mild cognitive impairment (MCI). Modification with Hcy-thiolactone generates auto-immunogenic -Hcy-protein. We tested a hypothesis that anti--Hcy-protein autoantibodies predict cognition in individuals with MCI participating in a randomized, double-blind, placebo-controlled VITACOG trial of B vitamins.
Participants with MCI (n = 196, 76.8 years old, 60% women) were randomly assigned to receive a daily dose of folic acid (0.8 mg), vitamin B (0.5 mg), and B (20 mg) (n = 98) or placebo (n = 98) for 2 years. Cognition was analyzed by neuropsychological tests. Brain atrophy was quantified in a subset of patients (n = 167) by magnetic resonance imaging. Anti -Hcy-protein auto-antibodies were quantified by enzyme-linked immunosorbent assay. Associations among anti--Hcy-protein autoantibodies, cognition, and brain atrophy were examined by multiple regression analysis.
At baseline, anti--Hcy-protein autoantibodies were significantly associated with impaired global cognition (Mini-Mental State Examination [MMSE]), episodic memory (Hopkins Verbal Learning Test-revised), and attention/processing speed (Map Search). At the end of the study, anti--Hcy-protein autoantibodies were associated with impaired global cognition (MMSE) and attention/processing speed (Trail Making A). In the placebo group, baseline anti--Hcy-protein autoantibodies predicted, independently of Hcy, global cognition (Telephone Inventory for Cognitive Status modified [TICS-m]; MMSE) and attention/processing speed (Trail Making A) but not brain atrophy, at the end of study. B-vitamin treatment abrogated association of anti--Hcy-protein autoantibodies with cognition.
These findings suggest that anti--Hcy-protein autoantibodies can impair functional (attention/processing speed and global cognition), but not structural (brain atrophy), aspects of cognition. Anti--Hcy-protein autoantibodies are a new factor associated with impaired cognition, which could be ameliorated by B vitamins.
同型半胱氨酸(Hcy)及其相关代谢产物水平升高会加速阿尔茨海默病的发展。降低Hcy水平的B族维生素可减缓轻度认知障碍(MCI)患者的脑萎缩/认知衰退。Hcy-硫内酯修饰会产生自身免疫原性的-Hcy-蛋白。我们检验了一个假设,即在参与一项关于B族维生素的随机、双盲、安慰剂对照VITACOG试验的MCI个体中,抗-Hcy-蛋白自身抗体可预测认知情况。
MCI参与者(n = 196,76.8岁,60%为女性)被随机分配,连续2年每日服用叶酸(0.8毫克)、维生素B(0.5毫克)和B(20毫克)(n = 98)或安慰剂(n = 98)。通过神经心理学测试分析认知情况。通过磁共振成像对部分患者(n = 167)的脑萎缩进行量化。通过酶联免疫吸附测定法对抗-Hcy-蛋白自身抗体进行量化。通过多元回归分析检验抗-Hcy-蛋白自身抗体、认知和脑萎缩之间的关联。
在基线时,抗-Hcy-蛋白自身抗体与整体认知障碍(简易精神状态检查表[MMSE])、情景记忆(修订后的霍普金斯言语学习测试)以及注意力/处理速度(地图搜索)显著相关。在研究结束时,抗-Hcy-蛋白自身抗体与整体认知障碍(MMSE)和注意力/处理速度(连线测验A)相关。在安慰剂组中,基线时抗-Hcy-蛋白自身抗体独立于Hcy可预测研究结束时的整体认知(改良认知状态电话量表[TICS-m];MMSE)和注意力/处理速度(连线测验A),但不能预测脑萎缩情况。B族维生素治疗消除了抗-Hcy-蛋白自身抗体与认知之间的关联。
这些发现表明,抗-Hcy-蛋白自身抗体可损害认知的功能方面(注意力/处理速度和整体认知),但不损害认知的结构方面(脑萎缩)。抗-Hcy-蛋白自身抗体是与认知障碍相关的一个新因素,B族维生素可能会改善这种情况。